Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC100 Multiple-Dose Safety in ALS
NCT03049046Phase 1Unknown
- Sponsor
- Chemigen
- Start
- Apr 2017
- Primary completion
- Jan 2018
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of caffeic acid phenethyl ester in amyotrophic lateral sclerosis (ALS) (4 arms), sponsored by Chemigen. Primary endpoint: Safety and Tolerability. Status: unknown.
02
Drugs
caffeic acid phenethyl ester
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03049046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049046.